In a phase II clinical trial performed on 78 patients with RA (MIDORA; NCT04163991), VIB4920 demonstrated an acceptable safety profile with a significant reduction of DAS28-CRP compared with the placebo group (57), confirming the relevance of using a TNC-based approach for the treatment of RA. Here, CRP is linked to rheumatoid arthritis.